Opportunity Information: Apply for PAR 14 116
Apply for PAR 14 116
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on May 23, 2014 and posted on Feb 26, 2014.
- Applicants must submit their applications by May 7, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses Public housing authorities/Indian housing authorities Native American tribal governments (Federally recognized) City or township governments County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) funding opportunity (PAR 14-116) is a National Institutes of Health (NIH) cooperative agreement designed to strengthen how quantitative imaging (QI) is used in cancer clinical trials, particularly for predicting and measuring how tumors respond to treatment. The central goal is to make imaging-based measurements more reliable, comparable, and clinically meaningful so they can be used as stronger evidence in therapeutic development and patient management. Because this is a U01 cooperative agreement, awardees should expect substantial NIH program involvement in shaping and coordinating aspects of the project compared with a typical investigator-initiated research grant.
The announcement emphasizes two complementary development paths. The first path focuses on advancing state-of-the-art quantitative imaging methods and software tools and then optimizing and validating them for potential use in single-site Phase 1 or Phase 2 clinical trials. This implies work that goes beyond a proof of concept and moves toward readiness for clinical trial use, including careful assessment of performance and consistency. Projects under this path would typically aim to show that a quantitative imaging approach can produce stable, interpretable measurements under controlled trial conditions and can feasibly fit into trial operations.
The second path targets the harder problem of scaling quantitative imaging to the realities of multicenter Phase 3 clinical trials. Multicenter trials introduce variability from different scanner manufacturers, imaging platforms, acquisition protocols, reconstruction settings, site workflows, and reader practices, all of which can undermine measurement consistency. To address this, the FOA encourages efforts to integrate existing and/or new QI methods in ways that make them robust across sites. This can include evaluating multimodal imaging strategies (for example, combining information across imaging types when appropriate), harmonizing how imaging data are collected and analyzed, standardizing display and interpretation approaches, and aligning clinical workflow methods so that imaging-derived endpoints can be used consistently across institutions. It also explicitly notes the value of testing performance across different cancer sites, recognizing that imaging challenges can differ substantially by tumor type and anatomic location.
From an applicant standpoint, the opportunity sits in the NIH health and education research space and is linked to CFDA numbers 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research). The award ceiling listed is $500,000, and there is no cost sharing or matching requirement. Key dates provided in the record include a posted date of February 26, 2014, an original closing date of February 5, 2017, a current closing date of May 7, 2017, and an archive date of June 7, 2017, indicating the opportunity is historical rather than currently open.
Eligibility is broad and spans many organization types, including public and private institutions of higher education, nonprofits (both 501(c)(3) and non-501(c)(3)), for-profit organizations (including small businesses), state and local governments, tribal governments and tribal organizations, public housing authorities/Indian housing authorities, special district governments, independent school districts, and others. The eligibility details also explicitly include a wide range of mission-focused institutions and communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and Asian American Native American Pacific Islander-serving institutions (AANAPISIs). Importantly, non-U.S. entities are eligible to apply, foreign institutions and foreign organizations are allowed, and foreign components (as defined by NIH policy) are permitted, which signals NIH interest in broad participation where it strengthens the science and improves generalizability.
Overall, the program is aimed at closing the gap between promising quantitative imaging techniques and their dependable, routine use as trial endpoints or decision-support tools in cancer therapy studies. It encourages applicants to treat quantitative imaging not just as a technical exercise but as a translational effort that must survive clinical variability, integrate into trial workflows, and demonstrate measurable performance across platforms, sites, and cancer settings. The full announcement was hosted on the NIH grants site at the link provided in the source text, and NIH’s Office of Extramural Research (OER) webmaster contact was listed for access or technical issues.
Frequently Asked Questions (FAQs)
What is the Quantitative Imaging for Evaluation of Response to Cancer Therapies (U01) opportunity?
It is an NIH cooperative agreement funding opportunity (U01) titled "Quantitative Imaging for Evaluation of Response to Cancer Therapies" (PAR 14-116). It is designed to strengthen how quantitative imaging (QI) is used in cancer clinical trials, especially for predicting and measuring tumor response to treatment.
What is the main goal of this funding opportunity?
The central goal is to make imaging-based measurements more reliable, comparable, and clinically meaningful so they can serve as stronger evidence in cancer therapeutic development and patient management.
What does it mean that this is a U01 cooperative agreement?
Because it is a U01 cooperative agreement, applicants should expect substantial NIH program involvement in shaping and coordinating aspects of the project compared with a typical investigator-initiated research grant.
What types of projects does the FOA emphasize?
The announcement emphasizes two complementary development paths: (1) advancing and validating QI methods/software for potential use in single-site Phase 1 or Phase 2 trials, and (2) scaling QI approaches so they are robust enough for multicenter Phase 3 trials.
What is the first development path focused on?
The first path focuses on advancing state-of-the-art quantitative imaging methods and software tools and then optimizing and validating them for potential use in single-site Phase 1 or Phase 2 clinical trials. This goes beyond proof-of-concept toward clinical-trial readiness, including careful assessment of performance and consistency.
What is the second development path focused on?
The second path targets the challenge of implementing quantitative imaging in multicenter Phase 3 clinical trials, where variability across sites and platforms can undermine measurement consistency. Projects are encouraged to make QI methods more robust across sites and more consistent for use as imaging-derived endpoints.
Why are multicenter Phase 3 trials particularly challenging for quantitative imaging?
Multicenter trials can introduce variability due to different scanner manufacturers, imaging platforms, acquisition protocols, reconstruction settings, site workflows, and reader practices. These differences can reduce measurement consistency and comparability across institutions.
What strategies does the FOA encourage to improve robustness across sites?
The FOA encourages integrating existing and/or new QI methods to improve cross-site robustness. Examples described include harmonizing imaging data collection and analysis, standardizing display and interpretation approaches, and aligning clinical workflow methods so imaging-derived endpoints can be used consistently across institutions.
Does the FOA allow or encourage multimodal imaging approaches?
Yes. It notes that evaluating multimodal imaging strategies can be appropriate, including combining information across imaging types when suitable.
Does the FOA emphasize testing across different cancer types or anatomic sites?
Yes. It explicitly notes the value of testing performance across different cancer sites, recognizing that imaging challenges can differ substantially by tumor type and anatomic location.
What clinical trial phases are referenced in the FOA?
The opportunity discusses readiness and validation for single-site Phase 1 or Phase 2 trials (first path) and robustness and standardization for multicenter Phase 3 trials (second path).
What is the maximum award amount listed for this opportunity?
The award ceiling listed in the record is $500,000.
Is cost sharing or matching required?
No. The record states there is no cost sharing or matching requirement.
What CFDA numbers are associated with this program?
The opportunity is linked to CFDA 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research).
Which agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
Is this opportunity currently open for applications?
No. The dates provided indicate it is historical rather than currently open. The record shows an archive date of June 7, 2017.
What dates are listed in the record for this opportunity?
The record includes a posted date of February 26, 2014; an original closing date of February 5, 2017; a current closing date of May 7, 2017; and an archive date of June 7, 2017.
Who is eligible to apply?
Eligibility is broad and includes many organization types such as public and private institutions of higher education; nonprofits (501(c)(3) and non-501(c)(3)); for-profit organizations (including small businesses); state and local governments; tribal governments and tribal organizations; public housing authorities/Indian housing authorities; special district governments; independent school districts; and others.
Are mission-focused institutions like HBCUs and Hispanic-serving institutions included in eligibility?
Yes. The eligibility details explicitly include HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, and AANAPISIs.
Are non-U.S. (foreign) organizations allowed to apply?
Yes. The information provided states non-U.S. entities are eligible to apply, foreign institutions and foreign organizations are allowed, and foreign components (as defined by NIH policy) are permitted.
What is the program trying to achieve in practical terms for cancer trials?
It is aimed at closing the gap between promising quantitative imaging techniques and their dependable, routine use as clinical trial endpoints or decision-support tools in cancer therapy studies, including surviving real-world clinical variability and fitting into trial workflows.
Where was the full announcement hosted, and who was listed for technical access issues?
The full announcement was hosted on the NIH grants site at the link provided in the source text, and the NIH Office of Extramural Research (OER) webmaster contact was listed for access or technical issues.
Browse more opportunities from the same category: Education Health
Next opportunity: 2015 National Urban and Community Forestry Challenge Cost Share Grant Program
Previous opportunity: Additional Research Training Slots for NIDA Supported NRSA Institutional Training (T32) Grants (Admin Supp)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 14 116
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 14 116) also looked into and applied for these:
| Funding Opportunity |
|---|
| Accelerating Improvements in the HIV Care Continuum (R01) Apply for PA 14 132 Funding Number: PA 14 132 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R34) Apply for PA 14 135 Funding Number: PA 14 135 Agency: National Institutes of Health Category: Education Health Funding Amount: $225,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R21) Apply for PA 14 136 Funding Number: PA 14 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Prevention and Treatment of Substance Using Populations with or at Risk for HCV (R01) Apply for PA 14 137 Funding Number: PA 14 137 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R21) Apply for PA 14 141 Funding Number: PA 14 141 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Community Partnerships to Advance Research (CPAR) (R01) Apply for PA 14 142 Funding Number: PA 14 142 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Research (CPAR) (R15) Apply for PA 14 140 Funding Number: PA 14 140 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Additional Research Training Positions for NIAAA , NIDA , or NCI Supported NRSA Institutional Training (T32) Grants (Admin Supp) Apply for PA 14 146 Funding Number: PA 14 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) Apply for PAR 14 152 Funding Number: PAR 14 152 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts (U01) Apply for PAR 14 160 Funding Number: PAR 14 160 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R03) Apply for PA 14 164 Funding Number: PA 14 164 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R21) Apply for PA 14 162 Funding Number: PA 14 162 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Effects of Cannabis Use and Cannabinoids on the Developing Brain (R01) Apply for PA 14 163 Funding Number: PA 14 163 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Genetics or Epigenetics of Substance Abuse (DP2) Apply for RFA DA 15 006 Funding Number: RFA DA 15 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Phase Clinical Trials in Imaging and Image Guided Interventions (R01) Apply for PAR 14 166 Funding Number: PAR 14 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Physical Sciences Oncology Centers (U54) Apply for PAR 14 169 Funding Number: PAR 14 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Avenir Award Program for Research on Substance Abuse and HIV/AIDS (DP2) Apply for RFA DA 15 007 Funding Number: RFA DA 15 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R21) Apply for PA 14 176 Funding Number: PA 14 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Healthy Habits Timing for Developing Sustainable Healthy Behaviors in Children and Adolescents (R01) Apply for PA 14 177 Funding Number: PA 14 177 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| mHealth Tools for Underserved Populations with Chronic Conditions to Promote Effective Patient Provider Communication, Adherence to Treatment and Self Management (R01) Apply for PA 14 180 Funding Number: PA 14 180 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 14 116", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.